

Objectives

List the criteria for when monitoring is appropriate. Describe the role of population

Ratt

estimates in concentration monitoring.

Objectives

Estimate PK parameters in a specific patient and calculate drug concentrations expected at the time of sampling. Understand and know how to avoid common errors when using drug concentrations to individualize drug

RAH

LOWA PHARMACY therapy.

Reading

- Herman RA: General Approaches to Clinical Pharmacokinetic Monitoring. In *Pharmacokinetics in Drug Discovery and Development*, by Ronald Schoenwald, pp 115-126, Boca Raton, FL: CRC Press LLC, 2002.
- Sawchuk RJ, Zaske DE: Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: Gentamicin in burn patients. J Pharmacokin Biopharm 1976;4:183-195.




RaH

Basic Pharmacokinetics

+ L iberation **A bsorption D** istribution **+ E** limination **T** herapeutic Drug Monitoring





Applied Pharmacokinetics

Drug Concentration Pharmacokinetic

Principles

Clinical or Pharmacological Response To optimize drug therapy for the patient. UIHO

Ratt

hir

Blood Level Determinations


UIHO

8

fin the second s

PHARMACY


Steady State Concentration



UNIVIERSITY OF IOWA


Blood Level Determinations

Determine the best possible safe dosing regimen.



Blood Level Determinations Determine the best possible safe dosing regimen.

Solution Maintain optimal therapy.



RAH





Ratt


Blood Level Determinations

- Determine the best possible safe dosing regimen.
- **Maintain optimal therapy.**
- Aid in the identification of patient noncompliance.





Drug Level Determinations




When do we draw levels?




fin








Sometimes a single level.



fin the second s

RAH 14






Ratt


16

When is the peak drawn?

fin.



Times & Concentrations



- C_{pk} is where the blue line intersects B
- **T**[']_{inf} is the time from C to P

hiii

IOWA

PHARMACY

• T_{pinf} is the time from P to B

- The peak (C_{pk}) is measured when distribution is complete (**B**)
- The trough (C_{tr}) is measured within 30 minutes of the administration (C)

UIHC

Optimum Peak Sampling Times

Sentamicin and Tobramycin **Infuse over 30 minutes**

* Draw the peak 30 minutes after the infusion stops.

Se Vancomycin

★ Dose ≤ 1.25 g infuse over 90 minutes
★ Dose 1.5 - 2 g infuse over 120 minutes
★ Draw the peak 60 minutes after the infusion stops.

RAH


hn

How are drug concentrations (Chapter 3, pp 30-38) measured?

- **Sample Collection**
 - *** Venous vs Arterial**
 - ✤ Plasma vs Serum
- San Assay Method
 - ***** Microbiological
 - ✤ HPLC
 - **∦** GLC
 - **∦** Radio-immunoassay
 - ***** Enzyme Meditated Immunoassy (EMIT)
- States Units

וונת

PHARMACY




 $D_{new} = \frac{D_{current} \cdot C_{desired}}{C_{ss,measured}}$

h11

PHARMACY

Note: D (dose) involves two components amount and interval: e.g.

- Lidocaine 1 mg/Hr
- Theophylline SR 200 mg/12 Hr



RAH 21



Se You have 2 options:

- ***** Take the ratio times the amount (dose):
 - **≻** 200 mg * 12/8 = 300 mg (keeping the interval Q12H).
 - ▷ D_{new} = 300 mg Q12H

 $> D_{new} = 200 \text{ mg Q8H}$

- % Take 1 over the ratio times the interval (denominator)
 - > 12 Hr * 8/12 = 8 Hr and keep 200 mg dose




ורח




RAH 23


Individualizing Drug Therapy


Intermittent infusions * Target Concentrations *** Volume of distribution *** Elimination rate **Prospectively * Population Estimates Retrospectively * Blood Level Data**











Sawchuk - Zaske Approach to **Dosage Adjustment** Calculate the new peak. $C_{ss,pk} = \frac{R_0}{V_{ss} \cdot k_e} \cdot \frac{\left(1 - e^{-k_e t_{inf}}\right)}{\left(1 - e^{-k_e \tau}\right)}$ **8** Calculate the new trough. $C_{ss,tr} = C_{ss,pk} \cdot e^{-k_e(\tau - t_{inf})}$



Single drug concentration:

- * When using the D_{New} equation to insure valid recommendations are made, the measured concentration should be obtained at steady state. Check to see that the concentration was measured at least 5 times the average elimination half-life for the drug.
- * The $D_{Current}$ can be adjusted by multiplying the dose by the concentration ratio, or dividing the interval by the ratio.



Peak and Trough

- * When calculating the rate of elimination (K_e) make sure the correct time is used in the denominator Equation 1.
- * The time term in the denominator exponent in equation 2 t_{pk} is elapsed time from the start of the infusion to when the peak is measured minus the length of the infusion (which is the time post infusion $-t_{pinf}$).



Peak and Trough

ווח

PHARMACY

- ***** Equation 4 there are two common errors:
 - R₀ is rate of input dose in mg divided by the length of infusion (hr.)
 - Do not subtract the trough concentration from the C₀; you must multiply the exponent term times the trough then subtract this product from C₀.
- * Equation 5 when calculating a dosing interval do not use the calculated value, but choose a practical dosing interval, Q6H, Q8H, Q12H or Q24H.





Peak and Trough

- ***** When you calculate the new infusion rate (\mathbf{R}_0) :
 - Convert the rate to a dose in mg by multiplying by the length of the infusion.
 - Then round to a practical dose. E.g. aminoglycosides round to the nearest 10 mg increment and vancomycin round to the nearest 250 mg increment.
- When calculating the peak and trough (Equations 7 & 8) use the practical dosing interval that you chose and use the practical R₀ that you chose as well.



Case: BJ 67 YO WF

- BJ is a 67 YO 5'5" woman with cellulitis from Staph aureus.
 - ★ Her weight is 70 Kg (IBW = 57 Kg)
 - ***** Her serum creatinine is 1.3 mg/dl.
 - ***** Her measured CrCl was 44.7 ml/min.
- To give you a target peak of about 36 mg/L and trough of 15 mg/L:
 - * What dose (mg) of vancomycin would you recommend for initiation of therapy?
 - ***** And what dosing interval?





Sawchuk-Zaske Approach Equation 1 Prospectively estimate K_e.

*Normally you would need to first estimate CrCl from Cockcroft & Gault, but note that the measured CrCl was given to you, so use that.

Equation 2

***** Determine the half-life (from K_e).

UNIVIERSITY OF JOWA UIHC HOSPITALS & CLINICS

Sawchuk-Zaske Approach

Equation 3

***** Prospectively C_0 is your target peak concentration (here 36 mg/dl) so no calculation is necessary.

Equation 4

***** Prospectively estimate V_{ss} from the V_d , factor for vancomycin (here 0.7 L/Kg).




Sawchuk-Zaske Approach © Equation 5

- * Now you can estimate the dosing interval from the target peak and trough and the calculated K_e.
- *** You must select a practical Tau.**

***** Remember to select a practical dose.

- **Equation 6**
 - ***** Now use the practical Tau to determine the dose.
 - * Equation 6 gives you R_0 , the rate of infusion, so to get the dose you have to take the length of the infusion times R_0 .





chosen give you a steady state peak and trough near your targets.

Case: Vancomycin Retrospective

- **RW** is a 19 YO 5'6" woman with cellulitis from *Staph aureus*.
 - **Her weight is 68 Kg**
- She has been on vancomycin 1 Gm Q12H for 5 days.
 - ***** Pk/Tr came back at 17.0 and 4.1 mg/L
 - ★ The Pk was measured 60 minutes after the 90 minute infusion.
 - * The skin grafts still show signs of cellulitis and the physician wants to increase the dose
- What dose (mg) of vancomycin and what dosing interval would you recommend to clear the infection?

Summary Observation

- Properly collected serum drug concentrations can be very useful to optimize drug therapy for those agents that have a narrow therapeutic window.
- They can be used to calculate patient specific PK parameters and then make dosage adjustments.
- However, it is essential the drug concentrations used to optimize therapy be properly obtained and that the pharmacokinetic equations used to individualize drug therapy be utilized correctly.